NIKKEI 225
38,185.90 -16.47 (-0.04%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.29 +0.30 (+0.38%) GOLD FUTURES
2,315.00 -7.30 (-0.31%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,075.50 -910.55 (-1.82%)
CASI Pharmaceuticals, Inc. (CASI)
| Previous close | 2.6600 |
| Open | 2.7450 |
| Bid | 0.0000 x 0 |
| Ask | 2.7400 x 100 |
| Day's range | 2.6111 - 2.7450 |
| 52-week range | 1.8500 - 8.4800 |
| Volume | |
| Avg. volume | 203,304 |
| Market cap | 35.38M |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0200 |
| Earnings date | 24 Apr 2024 - 29 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
Simply Wall St.Analysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI)
With the business potentially at an important milestone, we thought we'd take a closer look at CASI Pharmaceuticals...
PR NewswireCASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link:
- PR Newswire
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
